Pemetrexed injected into spinal fluid for lung cancer that spread to brain lining
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a treatment called intrathecal pemetrexed, which is chemotherapy given directly into the fluid around your brain and spine. It's for people with a specific type of lung cancer that has spread to the lining of the brain or spinal cord after targeted therapy stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that has spread to the lining of your brain or spinal cord (leptomeningeal metastasis).
- Your cancer has stopped responding to a targeted therapy pill (TKI), and you have a specific gene change like EGFR, ALK, ROS1, RET, BRAF, NTRK, or KRAS.
- You are able to walk and care for yourself (ECOG performance status 0–2), and your doctor expects you to live at least 3 more months.
- You have not had chemotherapy injected into your spinal fluid before.
- Your kidneys, liver, and bone marrow are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at spinal fluid (also called CSF) in adults with EGFR-mutant lung cancer that has spread to the lining around the brain/spinal cord. The goal is to better understand the disease and what the spinal fluid tests may show to guide care.
This study tests whether a drug called pemetrexed, given directly into the fluid around your brain through a small implanted device, is safe and effective for treating lung cancer that has spread to the lining of the brain. It is for people whose cancer has a specific genetic change (EGFR, ALK, or ROS1) and who have already tried standard targeted pills that no longer control their disease.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.